Table 2 Pathology of invasive MBCs in the general population from SEER and BRCA2 MBCs and ORs in predicting male BRCA2 mutation carrier status

Total^b

6351

326

 Ductal carcinoma

5265

86.2

253

95.1

Reference

Reference

 Lobular carcinoma

82

1.5

4

1.5

1.02 (0.37–2.79)

1.00 (0.36–2.74)

 Medullary Carcinoma

16

0.3

2

0.8

2.60 (0.59–11.38)

2.34 (0.52–10.39)

 0–1

1699

34.9

44

29.5

Reference

Reference

 2

1990

40.9

70

47.0

1.36 (0.93.–1.99)

1.37 (0.93–2.01)

 3–4

1181

24.2

35

23.5

1.14 (0.73–1.77)

1.11 (0.72–1.73)

 Grade 1

632

12.9

8

3.5

Reference

Reference

 Grade 2

2432

49.7

92

39.8

2.99 (1.44–6.19)

2.98 (1.44–6.19)

 Grade 3

1834

37.4

131

56.7

5.64 (2.75–11.60)

5.53 (2.69–11.39)

 Negative

2773

58.0

123

50.2

Reference

Reference

 Positive

2009

42.0

122

49.8

1.37 (1.05–1.78)

1.28 (0.98–1.67)

 Negative

229

5.3

8

3.3

Reference

Reference

 Positive

4064

94.7

236

96.7

1.66 (0.81–3.41)

1.95 (0.93–4.06)

 Negative

627

15.0

30

13.2

Reference

Reference

 Positive

3562

85.0

198

86.8

1.16 (0.79–1.72)

1.30 (0.88–1.92)

 Negative

627

87.8

126

83.4

Reference

Reference

 Positive

87

12.2

25

16.6

1.43 (0.88–2.32)

1.30 (0.79–2.13)

 ER+ and/or PR+, HER2−

608

87.5

118

81.9

Reference

Reference

 ER+ and/or PR+, HER2+

80

11.5

22

15.3

1.42 (0.85–2.36)

1.28 (0.76–2.17)

 ER−, PR−, HER2+

7

1.0

2

1.4

1.47 (0.30–7.18)

1.09 (0.22–5.45)

 Triple-negative (ER−, PR−, HER2−)

0

0.0

2

1.4

–

–

 ER+ and/or PR+, HER2− vs. others

1.54 (0.95–2.49)

1.38 (0.84–2.27)